SG11202000331YA - Therapeutic modulators of the reverse mode of atp synthase - Google Patents
Therapeutic modulators of the reverse mode of atp synthaseInfo
- Publication number
- SG11202000331YA SG11202000331YA SG11202000331YA SG11202000331YA SG11202000331YA SG 11202000331Y A SG11202000331Y A SG 11202000331YA SG 11202000331Y A SG11202000331Y A SG 11202000331YA SG 11202000331Y A SG11202000331Y A SG 11202000331YA SG 11202000331Y A SG11202000331Y A SG 11202000331YA
- Authority
- SG
- Singapore
- Prior art keywords
- january
- international
- pct
- july
- viii
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000006682 Warburg effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1711250.9A GB201711250D0 (en) | 2017-07-13 | 2017-07-13 | Cancer therapy |
| GBGB1715756.1A GB201715756D0 (en) | 2017-09-28 | 2017-09-28 | Disclosure |
| GBGB1715758.7A GB201715758D0 (en) | 2017-09-28 | 2017-09-28 | Disclosing |
| GBGB1715938.5A GB201715938D0 (en) | 2017-10-01 | 2017-10-01 | Disclosure |
| GBGB1716492.2A GB201716492D0 (en) | 2017-10-09 | 2017-10-09 | Disclosure |
| GBGB1800092.7A GB201800092D0 (en) | 2018-01-04 | 2018-01-04 | Disclosure |
| GBGB1800291.5A GB201800291D0 (en) | 2018-01-08 | 2018-01-08 | Disclosure |
| GBGB1800581.9A GB201800581D0 (en) | 2018-01-15 | 2018-01-15 | Disclosure |
| PCT/EP2018/051127 WO2018134265A1 (en) | 2017-01-17 | 2018-01-17 | Therapeutic inhibitors of the reverse mode of atp synthase |
| GBGB1801536.2A GB201801536D0 (en) | 2018-01-30 | 2018-01-30 | Disclosure |
| GBGB1806421.2A GB201806421D0 (en) | 2018-04-19 | 2018-04-19 | Disclosure |
| GBGB1808331.1A GB201808331D0 (en) | 2018-05-21 | 2018-05-21 | Disclosure |
| GBGB1809497.9A GB201809497D0 (en) | 2018-06-08 | 2018-06-08 | Disclosure |
| GBGB1810236.8A GB201810236D0 (en) | 2018-06-21 | 2018-06-21 | Disclosure |
| GBGB1811188.0A GB201811188D0 (en) | 2018-07-08 | 2018-07-08 | Disclosure |
| PCT/EP2018/069175 WO2019012149A1 (en) | 2017-07-13 | 2018-07-13 | THERAPEUTIC MODULATORS OF THE INVERSE MODE OF ATP SYNTHASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000331YA true SG11202000331YA (en) | 2020-02-27 |
Family
ID=65001115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000331YA SG11202000331YA (en) | 2017-07-13 | 2018-07-13 | Therapeutic modulators of the reverse mode of atp synthase |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200306253A1 (he) |
| EP (1) | EP3652156A1 (he) |
| JP (2) | JP2021510365A (he) |
| CN (1) | CN111278810A (he) |
| AU (3) | AU2018298892B2 (he) |
| BR (1) | BR112019028172A2 (he) |
| CA (1) | CA3099077A1 (he) |
| CO (1) | CO2020001107A2 (he) |
| IL (1) | IL271845B2 (he) |
| MA (1) | MA49564A (he) |
| PH (1) | PH12020551543A1 (he) |
| RU (1) | RU2020105742A (he) |
| SG (1) | SG11202000331YA (he) |
| WO (1) | WO2019012149A1 (he) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021186325A1 (en) | 2020-03-15 | 2021-09-23 | Forrest Michael David | Almitrine for treating the hypoxemia of a coronavirus infection |
| CN111983241B (zh) * | 2020-09-04 | 2022-05-20 | 四川大学华西医院 | 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法 |
| EP4281034A1 (en) | 2021-01-24 | 2023-11-29 | Forrest, Michael, David | Inhibitors of atp synthase - cosmetic and therapeutic uses |
| WO2023047151A1 (en) | 2021-09-22 | 2023-03-30 | Forrest Michael David | Cancer biomarkers for susceptibility to treatment by almitrine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1256513A (he) | 1968-10-02 | 1971-12-08 | ||
| FR2667243B1 (fr) * | 1990-09-27 | 1994-11-04 | Adir | Utilisation de s derives de la triazine et de la pyrimidine pour l'obtention de medicaments reversant la resistance aux agents anticancereux et antimalariques. |
| US5869478A (en) | 1995-06-07 | 1999-02-09 | Bristol-Myers Squibb Company | Sulfonamido substituted benzopyran derivatives |
| US6916813B2 (en) | 2001-12-10 | 2005-07-12 | Bristol-Myers Squibb Co. | (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase |
| US6846836B2 (en) | 2003-04-18 | 2005-01-25 | Bristol-Myers Squibb Company | N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase |
| US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| EP3486653A1 (en) * | 2007-05-24 | 2019-05-22 | The United States Government as represented by The Department of Veterans Affairs | Treatment of skeletal muscle disorder using ent2 |
| SG10201601507YA (en) | 2010-11-29 | 2016-04-28 | Galleon Pharmaceuticals Inc | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
| CN105693806A (zh) * | 2016-04-23 | 2016-06-22 | 何华琼 | 一种二甲磺酸阿米三嗪的药物组合物及其医药用途 |
-
2018
- 2018-07-13 SG SG11202000331YA patent/SG11202000331YA/en unknown
- 2018-07-13 CN CN201880058860.7A patent/CN111278810A/zh active Pending
- 2018-07-13 EP EP18746115.7A patent/EP3652156A1/en active Pending
- 2018-07-13 AU AU2018298892A patent/AU2018298892B2/en active Active
- 2018-07-13 RU RU2020105742A patent/RU2020105742A/ru unknown
- 2018-07-13 JP JP2019572836A patent/JP2021510365A/ja active Pending
- 2018-07-13 WO PCT/EP2018/069175 patent/WO2019012149A1/en unknown
- 2018-07-13 BR BR112019028172-0A patent/BR112019028172A2/pt active Search and Examination
- 2018-07-13 MA MA049564A patent/MA49564A/fr unknown
- 2018-07-13 US US16/629,390 patent/US20200306253A1/en active Pending
- 2018-07-13 IL IL271845A patent/IL271845B2/he unknown
- 2018-07-13 CA CA3099077A patent/CA3099077A1/en active Pending
-
2020
- 2020-01-11 PH PH12020551543A patent/PH12020551543A1/en unknown
- 2020-01-30 CO CONC2020/0001107A patent/CO2020001107A2/es unknown
-
2022
- 2022-09-19 AU AU2022235526A patent/AU2022235526A1/en not_active Abandoned
-
2023
- 2023-06-22 JP JP2023102869A patent/JP2023123664A/ja active Pending
-
2024
- 2024-01-16 AU AU2024200288A patent/AU2024200288A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12020551543A1 (en) | 2020-10-26 |
| AU2024200288A1 (en) | 2024-02-08 |
| IL271845B1 (he) | 2024-02-01 |
| CN111278810A (zh) | 2020-06-12 |
| US20200306253A1 (en) | 2020-10-01 |
| JP2023123664A (ja) | 2023-09-05 |
| AU2022235526A1 (en) | 2022-10-13 |
| RU2020105742A (ru) | 2021-08-13 |
| CO2020001107A2 (es) | 2020-05-15 |
| AU2018298892A1 (en) | 2020-02-20 |
| BR112019028172A2 (pt) | 2020-10-06 |
| AU2018298892B2 (en) | 2022-06-23 |
| EP3652156A1 (en) | 2020-05-20 |
| IL271845B2 (he) | 2024-06-01 |
| MA49564A (fr) | 2021-04-28 |
| WO2019012149A1 (en) | 2019-01-17 |
| JP2021510365A (ja) | 2021-04-22 |
| CA3099077A1 (en) | 2019-01-17 |
| IL271845A (he) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201809857TA (en) | Anti-CTLA-4 Antibodies | |
| SG11201900947RA (en) | Tlr7/8 antagonists and uses thereof | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11202000331YA (en) | Therapeutic modulators of the reverse mode of atp synthase | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201810519XA (en) | A rinse composition, a method for forming resist patterns and a method for making semiconductor devices | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib |